Thr298
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr298  -  SSFA2 (human)

Site Information
tANRLMktLskLNLC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12217922

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:
lung ( 2 ) , NCI-H1650 (pulmonary) ( 3 )

References 

1

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

2

Ren H (2011) CST Curation Set: 11787; Year: 2011; Biosample/Treatment: cell line, RP104/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Possemato A (2009) CST Curation Set: 8048; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info